The Gateway to Better Health

We are committed to bringing effective medicines with distinct safety and dosing advantages to underserved patients by using the gut as the gateway to better health.
Learn About Us

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
~11 Million people in the U.S. with IBS-C
Impact

Making Better Medicine For Patients In Need

We have created a unique discovery platform that mimics key aspects of the human GI tract, enabling us to develop exceptional product candidates in a rapid and cost efficient manner.

Our Approach To Better Medicine

“Everyone here is excited about what we’re creating and what it could mean for patients.”

– Kelli, HR

Make An Impact With Us

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
MARKETED
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX8940
GI Indications
(TGR5 Agonist)
RDX011
GI Indications
(NHE3 Inhibitor)
RDX023
GI Indications
(FXR Agonist)
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX7675
Hyperkalemia
(Potassium Binder)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)